Galena Biopharma (GALE) to Present GALE-401 Phase 1 Data at ASH
Tweet Send to a Friend
Galena Biopharma (Nasdaq: GALE) announced that data from the Company's Phase 1 clinical trials of GALE-401, or Anagrelide Controlled Release ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
